Qinghai Spring Medicinal Resources Technology Second Quarter 2024 Earnings: CN¥0.056 loss per share (vs CN¥0.037 loss in 2Q 2023)

Qinghai Spring Medicinal Resources Technology (SHSE:600381) Second Quarter 2024 Results

Key Financial Results

• Revenue: CN¥53.9m (up 5.5% from 2Q 2023).
• Net loss: CN¥33.0m (loss widened by 51% from 2Q 2023).
• CN¥0.056 loss per share (further deteriorated from CN¥0.037 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Qinghai Spring Medicinal Resources Technology shares are up 21% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Qinghai Spring Medicinal Resources Technology you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com